BR112020003022A2 - composição farmacêutica para o uso no crescimento de cabelo, modificação do couro cabeludo ou pele, cicatrização de uma ferida, promoção da osteogênese ou modificação do cabelo - Google Patents
composição farmacêutica para o uso no crescimento de cabelo, modificação do couro cabeludo ou pele, cicatrização de uma ferida, promoção da osteogênese ou modificação do cabelo Download PDFInfo
- Publication number
- BR112020003022A2 BR112020003022A2 BR112020003022-8A BR112020003022A BR112020003022A2 BR 112020003022 A2 BR112020003022 A2 BR 112020003022A2 BR 112020003022 A BR112020003022 A BR 112020003022A BR 112020003022 A2 BR112020003022 A2 BR 112020003022A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- hair
- milk
- administration
- acid
- Prior art date
Links
- 210000004209 hair Anatomy 0.000 title claims abstract description 146
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 118
- 210000004761 scalp Anatomy 0.000 title claims abstract description 64
- 230000011164 ossification Effects 0.000 title claims abstract description 25
- 230000004048 modification Effects 0.000 title claims abstract description 20
- 238000012986 modification Methods 0.000 title claims abstract description 20
- 230000003779 hair growth Effects 0.000 title claims abstract description 17
- 230000029663 wound healing Effects 0.000 title abstract description 32
- 150000004671 saturated fatty acids Chemical class 0.000 claims abstract description 62
- 150000003839 salts Chemical class 0.000 claims abstract description 30
- 239000008267 milk Substances 0.000 claims description 162
- 210000004080 milk Anatomy 0.000 claims description 162
- 235000013336 milk Nutrition 0.000 claims description 161
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 98
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 81
- 239000000194 fatty acid Substances 0.000 claims description 81
- 229930195729 fatty acid Natural products 0.000 claims description 81
- 150000004665 fatty acids Chemical class 0.000 claims description 78
- 238000011282 treatment Methods 0.000 claims description 68
- 235000021314 Palmitic acid Nutrition 0.000 claims description 49
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 49
- 238000011200 topical administration Methods 0.000 claims description 45
- 230000001737 promoting effect Effects 0.000 claims description 33
- 235000021355 Stearic acid Nutrition 0.000 claims description 30
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 30
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 30
- 239000008117 stearic acid Substances 0.000 claims description 30
- 150000004670 unsaturated fatty acids Chemical class 0.000 claims description 23
- 235000021122 unsaturated fatty acids Nutrition 0.000 claims description 22
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 claims description 17
- 235000021360 Myristic acid Nutrition 0.000 claims description 16
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims description 16
- 230000000051 modifying effect Effects 0.000 claims description 12
- 235000012424 soybean oil Nutrition 0.000 claims description 6
- 239000003549 soybean oil Substances 0.000 claims description 6
- 239000010985 leather Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 95
- 239000000047 product Substances 0.000 description 77
- 210000001519 tissue Anatomy 0.000 description 72
- 230000000694 effects Effects 0.000 description 49
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 45
- 239000000203 mixture Substances 0.000 description 45
- 108010016731 PPAR gamma Proteins 0.000 description 44
- 230000001965 increasing effect Effects 0.000 description 44
- 210000003491 skin Anatomy 0.000 description 44
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 41
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 35
- 102100025136 Macrosialin Human genes 0.000 description 35
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 30
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 30
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 30
- 239000005642 Oleic acid Substances 0.000 description 30
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 30
- 210000001789 adipocyte Anatomy 0.000 description 30
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 30
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 30
- 235000021313 oleic acid Nutrition 0.000 description 30
- 230000019612 pigmentation Effects 0.000 description 29
- 102000010445 Lactoferrin Human genes 0.000 description 26
- 108010063045 Lactoferrin Proteins 0.000 description 26
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 26
- 235000021242 lactoferrin Nutrition 0.000 description 26
- 229940078795 lactoferrin Drugs 0.000 description 26
- 210000002540 macrophage Anatomy 0.000 description 25
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 24
- 210000000988 bone and bone Anatomy 0.000 description 24
- 206010052428 Wound Diseases 0.000 description 23
- 208000027418 Wounds and injury Diseases 0.000 description 23
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 23
- 230000014509 gene expression Effects 0.000 description 23
- 210000003128 head Anatomy 0.000 description 23
- 235000020778 linoleic acid Nutrition 0.000 description 23
- 229960004232 linoleic acid Drugs 0.000 description 23
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 23
- 229960004488 linolenic acid Drugs 0.000 description 23
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- 239000000523 sample Substances 0.000 description 23
- 241000282414 Homo sapiens Species 0.000 description 20
- 230000008859 change Effects 0.000 description 19
- 239000010409 thin film Substances 0.000 description 18
- 102000001187 Collagen Type III Human genes 0.000 description 17
- 108010069502 Collagen Type III Proteins 0.000 description 17
- 241000700157 Rattus norvegicus Species 0.000 description 17
- 230000006872 improvement Effects 0.000 description 17
- 102000012422 Collagen Type I Human genes 0.000 description 16
- 108010022452 Collagen Type I Proteins 0.000 description 16
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 16
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 16
- 210000003022 colostrum Anatomy 0.000 description 14
- 235000021277 colostrum Nutrition 0.000 description 14
- 239000010408 film Substances 0.000 description 14
- 235000010469 Glycine max Nutrition 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 229960002969 oleic acid Drugs 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 235000003441 saturated fatty acids Nutrition 0.000 description 13
- 241000283690 Bos taurus Species 0.000 description 12
- 102000008186 Collagen Human genes 0.000 description 12
- 108010035532 Collagen Proteins 0.000 description 12
- 239000010775 animal oil Substances 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 108020004999 messenger RNA Proteins 0.000 description 12
- 239000002504 physiological saline solution Substances 0.000 description 12
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 12
- 235000015112 vegetable and seed oil Nutrition 0.000 description 12
- 239000008158 vegetable oil Substances 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 10
- 230000007547 defect Effects 0.000 description 9
- 239000012634 fragment Substances 0.000 description 9
- 210000003625 skull Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 210000004322 M2 macrophage Anatomy 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 230000007423 decrease Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000003648 hair appearance Effects 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 230000017423 tissue regeneration Effects 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 230000003716 rejuvenation Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- 108010009992 CD163 antigen Proteins 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 6
- 102100025831 Scavenger receptor cysteine-rich type 1 protein M130 Human genes 0.000 description 6
- 239000005862 Whey Substances 0.000 description 6
- 102000007544 Whey Proteins Human genes 0.000 description 6
- 108010046377 Whey Proteins Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000000130 stem cell Anatomy 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 102000008137 Bone Morphogenetic Protein 4 Human genes 0.000 description 4
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 4
- 102000008131 Bone Morphogenetic Protein 7 Human genes 0.000 description 4
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 229920000954 Polyglycolide Polymers 0.000 description 4
- -1 acids fatty acids Chemical class 0.000 description 4
- 210000000577 adipose tissue Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 238000001000 micrograph Methods 0.000 description 4
- 239000004633 polyglycolic acid Substances 0.000 description 4
- 230000000644 propagated effect Effects 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- 238000004659 sterilization and disinfection Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 101150066398 CXCR4 gene Proteins 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 102000000536 PPAR gamma Human genes 0.000 description 3
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 3
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 3
- 238000010191 image analysis Methods 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 108010034467 ribosomal protein P0 Proteins 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 208000019300 CLIPPERS Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 208000006735 Periostitis Diseases 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 208000021930 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids Diseases 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002600 fibrillogenic effect Effects 0.000 description 2
- 230000037308 hair color Effects 0.000 description 2
- 230000003681 hair reduction Effects 0.000 description 2
- 230000003752 improving hair Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 210000003460 periosteum Anatomy 0.000 description 2
- 235000020185 raw untreated milk Nutrition 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- DJCQJZKZUCHHAL-UHFFFAOYSA-N (Z)-9-Pentadecensaeure Natural products CCCCCC=CCCCCCCCC(O)=O DJCQJZKZUCHHAL-UHFFFAOYSA-N 0.000 description 1
- FGRBYDKOBBBPOI-UHFFFAOYSA-N 10,10-dioxo-2-[4-(N-phenylanilino)phenyl]thioxanthen-9-one Chemical compound O=C1c2ccccc2S(=O)(=O)c2ccc(cc12)-c1ccc(cc1)N(c1ccccc1)c1ccccc1 FGRBYDKOBBBPOI-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 108050000299 Chemokine receptor Proteins 0.000 description 1
- 102000009410 Chemokine receptor Human genes 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- PVNIQBQSYATKKL-UHFFFAOYSA-N Glycerol trihexadecanoate Natural products CCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCC PVNIQBQSYATKKL-UHFFFAOYSA-N 0.000 description 1
- 102000009875 Ki-67 Antigen Human genes 0.000 description 1
- 108010020437 Ki-67 Antigen Proteins 0.000 description 1
- 101100165560 Mus musculus Bmp7 gene Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 230000021839 RNA stabilization Effects 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-M Vaccenic acid Natural products CCCCCC\C=C/CCCCCCCCCC([O-])=O UWHZIFQPPBDJPM-FPLPWBNLSA-M 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 101150067309 bmp4 gene Proteins 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- UWHZIFQPPBDJPM-FPLPWBNLSA-N cis-vaccenic acid Chemical compound CCCCCC\C=C/CCCCCCCCCC(O)=O UWHZIFQPPBDJPM-FPLPWBNLSA-N 0.000 description 1
- 210000003690 classically activated macrophage Anatomy 0.000 description 1
- 229940096422 collagen type i Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical group 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003662 hair growth rate Effects 0.000 description 1
- 230000003699 hair surface Effects 0.000 description 1
- 230000003741 hair volume Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940098695 palmitic acid Drugs 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920006381 polylactic acid film Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 210000000603 stem cell niche Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 231100000732 tissue residue Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/20—Milk; Whey; Colostrum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
- A61K8/986—Milk; Derivatives thereof, e.g. butter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/10—Preparations for permanently dyeing the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Birds (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017249980 | 2017-12-26 | ||
| JP2017-249980 | 2017-12-26 | ||
| PCT/JP2018/047736 WO2019131712A1 (ja) | 2017-12-26 | 2018-12-26 | 増毛、頭皮若しくは皮膚の改質、創傷治癒、骨形成促進、または毛髪の改質に用いるための医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020003022A2 true BR112020003022A2 (pt) | 2020-08-25 |
Family
ID=67067427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020003022-8A BR112020003022A2 (pt) | 2017-12-26 | 2018-12-26 | composição farmacêutica para o uso no crescimento de cabelo, modificação do couro cabeludo ou pele, cicatrização de uma ferida, promoção da osteogênese ou modificação do cabelo |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11413321B2 (enExample) |
| EP (1) | EP3733173A4 (enExample) |
| JP (4) | JP6628946B2 (enExample) |
| KR (2) | KR20200102978A (enExample) |
| CN (2) | CN119326743A (enExample) |
| AU (1) | AU2018396512B2 (enExample) |
| BR (1) | BR112020003022A2 (enExample) |
| CA (1) | CA3070854A1 (enExample) |
| MX (2) | MX2020001764A (enExample) |
| SG (1) | SG11202000906YA (enExample) |
| TW (2) | TW202308606A (enExample) |
| WO (1) | WO2019131712A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6925072B1 (ja) | 2020-12-07 | 2021-08-25 | 株式会社Dr.Cherry | 毛髪改善のための組成物 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59172410A (ja) * | 1983-03-19 | 1984-09-29 | Suntory Ltd | 脂肪酸含有養毛組成物 |
| EP0116439A3 (en) | 1983-02-02 | 1986-01-29 | Suntory Limited | Fatty acid containing hair tonic composition |
| GB8603621D0 (en) * | 1986-02-14 | 1986-03-19 | Habib N | Modifying lipid structure of cell membranes |
| GB9026664D0 (en) * | 1990-12-07 | 1991-01-23 | Unilever Plc | Cosmetic composition |
| US5863938A (en) | 1991-03-01 | 1999-01-26 | Warner Lambert Company | Antibacterial-wound healing compositions and methods for preparing and using same |
| US5663208A (en) | 1991-03-01 | 1997-09-02 | Warner-Lambert Company | Antifungal wound healing compositions and methods for preparing and using same |
| ES2102813T3 (es) * | 1993-01-26 | 1997-08-01 | Horse Vitality Ltd | Composiciones farmaceuticas y dermocosmeticas que contienen calostro equino. |
| IT1290347B1 (it) * | 1997-02-18 | 1998-10-22 | Horse Vitality Ltd | Formulazioni farmaceutiche contenenti colostro e uso del colostro per il trattamento della caduta dei capelli |
| US6620427B2 (en) | 2001-04-24 | 2003-09-16 | Abbott Laboratories | Method for improving bone mineralization |
| EP1583512B3 (en) | 2002-12-12 | 2012-12-05 | R.B.T. (Rakuto Bio Technologies) Ltd. | USE of LIGNIN PEROXIDASE IN SKIN AND HAIR LIGHTENING |
| CU23256A1 (es) | 2003-03-20 | 2008-01-24 | Dalmer Lab Sa | EXTRACTO OBTENIDO A PARTIR DE FRUTOS DE ROYSTONEA REGIA UTILIZADO CONTRA LA HIPERPLASIA PROSTáTICA Y LA PROSTATITIS |
| TWI256893B (en) | 2003-03-25 | 2006-06-21 | Fancl Corp | Composition for promoting production of type I collagen and/or elastin |
| DE602004029058D1 (de) * | 2003-07-09 | 2010-10-21 | Shinonogi & Co Ltd | Inducer von atopischer dermatitis |
| JP2005179190A (ja) | 2003-12-16 | 2005-07-07 | Kao Corp | 創傷治癒促進剤 |
| KR101237316B1 (ko) | 2004-05-21 | 2013-02-28 | 타다시 고이노 | 두피두발용 조성물 |
| FR2872912B1 (fr) * | 2004-07-09 | 2007-03-02 | Centre Nat Rech Scient Cnrse | Nouveau systeme microfluidique et procede de capture de cellules |
| FR2873293B1 (fr) | 2004-07-21 | 2006-11-17 | Cerep Sa | Utilisation d'un acide gras pour la preparation d'une composition topique destinee a l'apaisement des reactions inflammatoires dues aux piqures d'hymenopteres a venin |
| EP2481389B1 (en) * | 2004-12-24 | 2016-05-04 | Dolphst Pty Ltd | Formulations and treatments for trichology |
| DE102006053692A1 (de) * | 2006-11-13 | 2007-08-23 | Henkel Kgaa | Oxidative Haarbehandlung mit verringerter Haarschädigung |
| WO2008147228A1 (en) * | 2007-05-31 | 2008-12-04 | Fonterra Corporate Research And Development Limited | Treatment or prevention of bone conditions |
| WO2009149537A1 (en) * | 2008-06-12 | 2009-12-17 | Christine Allen | Injectable polymer-lipid blend |
| NZ591037A (en) | 2008-07-15 | 2013-02-22 | Christopher Thanos | Wound healing using choroid plexus secreted proteins |
| JP5436929B2 (ja) | 2009-05-15 | 2014-03-05 | 花王株式会社 | まつ毛用化粧料 |
| WO2011039637A2 (en) | 2009-10-02 | 2011-04-07 | Foamix Ltd. | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| JP5348784B2 (ja) | 2009-12-28 | 2013-11-20 | 株式会社 資生堂 | 化粧料 |
| AU2011223730A1 (en) | 2010-03-02 | 2012-10-18 | Imagenetix, Inc. | Compositions comprising myristic acid and uses thereof |
| JP5927506B2 (ja) * | 2010-04-13 | 2016-06-01 | レルマダ セラピューティクス、インク． | １−メチル−２’，６’−ピペコロキシリダイドの皮膚医薬組成物および使用方法 |
| JP5534200B2 (ja) | 2010-06-25 | 2014-06-25 | ホーユー株式会社 | 薬剤評価方法 |
| US20120129789A1 (en) | 2010-11-18 | 2012-05-24 | Steven Yoelin | Compositions and methods for hair growth |
| US20120149775A1 (en) * | 2010-11-29 | 2012-06-14 | Shiseido Company, Ltd. | Methods for preventing and improving skin elastic property loss |
| US20160256505A1 (en) * | 2011-06-29 | 2016-09-08 | Junwu Xing | Fatty acid composition and plant extract and pharmaceutical preparation and application thereof |
| KR101918773B1 (ko) | 2012-05-03 | 2018-11-14 | 박시향 | 군소 추출물을 유효성분으로 포함하는 두피 개선 및 탈모 방지용 조성물 |
| BR112015001694A2 (pt) * | 2012-07-27 | 2017-07-04 | Khal Fardoussi Kassem | uso de uma composição para a fabricação de um medicamento para tratamento de distúrbios cutâneos e/ou distúrbios de proliferação celular anormal; composição; e método para preparar uma composição farmacêutica |
| IN2015DN03069A (enExample) * | 2012-09-14 | 2015-10-02 | Miracle Fruit Oil L L C | |
| US12414911B2 (en) | 2012-09-14 | 2025-09-16 | Miracle Fruit Oil L.L.C. | Topical compositions and methods of use |
| JP2015537028A (ja) | 2012-11-16 | 2015-12-24 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 皮膚修復のための組成物および方法 |
| EP2735303A1 (en) * | 2012-11-23 | 2014-05-28 | Pilosciences | Hair growth compositions and methods |
| JP6334211B2 (ja) * | 2013-03-29 | 2018-05-30 | 株式会社コーセー | 毛髪及び頭皮ケア組成物、及びその使用方法 |
| AU2014375268B2 (en) * | 2013-12-31 | 2019-11-14 | Pb & B Sa | Controlled release fatty acid compositions for use in body reconstruction and body-shaping |
| KR102122614B1 (ko) | 2014-02-25 | 2020-06-12 | 박시향 | 테트라셀미스 테트라셀레의 추출물을 유효 성분으로 함유하는 두피 개선 및 탈모 방지용 조성물 |
| KR102299276B1 (ko) | 2014-07-16 | 2021-09-09 | (주)아모레퍼시픽 | 납떼기콩 오일을 포함하는 조성물 |
| US10631973B2 (en) * | 2014-11-14 | 2020-04-28 | Washington University | Compostions and methods for tissue repair |
| TW201722464A (zh) | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| GB201519923D0 (en) * | 2015-11-11 | 2015-12-23 | Biovotec Dac And Biovotec As | Dry biocompatible disintegrateable films for delivering particulate egg shell membrane to a wound |
| WO2017146468A1 (ko) | 2016-02-23 | 2017-08-31 | 경희대학교 산학협력단 | 줄기세포의 효능 개선을 위한 조성물 및 방법 |
| JP6360944B2 (ja) | 2016-05-26 | 2018-07-18 | 株式会社食健 | 皮膚外用剤及びその製造方法 |
| CN106466327A (zh) | 2016-11-01 | 2017-03-01 | 侯建生 | 臭氧化油在皮肤疾病、肥胖和静脉血栓防治中的应用 |
| JP2024172410A (ja) | 2023-05-31 | 2024-12-12 | ダイヤゼブラ電機株式会社 | トロイダルコイル固定構造 |
-
2018
- 2018-12-26 KR KR1020207002999A patent/KR20200102978A/ko active Pending
- 2018-12-26 CN CN202411343607.XA patent/CN119326743A/zh active Pending
- 2018-12-26 AU AU2018396512A patent/AU2018396512B2/en active Active
- 2018-12-26 MX MX2020001764A patent/MX2020001764A/es unknown
- 2018-12-26 JP JP2019537016A patent/JP6628946B2/ja active Active
- 2018-12-26 TW TW111143564A patent/TW202308606A/zh unknown
- 2018-12-26 CN CN201880050803.4A patent/CN111050763B/zh active Active
- 2018-12-26 SG SG11202000906YA patent/SG11202000906YA/en unknown
- 2018-12-26 TW TW107147193A patent/TWI787423B/zh active
- 2018-12-26 CA CA3070854A patent/CA3070854A1/en active Pending
- 2018-12-26 WO PCT/JP2018/047736 patent/WO2019131712A1/ja not_active Ceased
- 2018-12-26 EP EP18895326.9A patent/EP3733173A4/en active Pending
- 2018-12-26 KR KR1020257013506A patent/KR20250058075A/ko active Pending
- 2018-12-26 US US16/635,221 patent/US11413321B2/en active Active
- 2018-12-26 BR BR112020003022-8A patent/BR112020003022A2/pt unknown
-
2019
- 2019-10-31 JP JP2019198071A patent/JP6732088B2/ja active Active
-
2020
- 2020-02-13 MX MX2022013816A patent/MX2022013816A/es unknown
- 2020-04-30 JP JP2020080412A patent/JP6765024B2/ja active Active
- 2020-04-30 JP JP2020080408A patent/JP6731129B1/ja active Active
-
2022
- 2022-06-29 US US17/853,335 patent/US12343369B2/en active Active
-
2025
- 2025-01-17 US US19/026,822 patent/US20250152649A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018396512B2 (en) | 2024-06-13 |
| US20250152649A1 (en) | 2025-05-15 |
| JP6732088B2 (ja) | 2020-07-29 |
| US20200246409A1 (en) | 2020-08-06 |
| JP2020128399A (ja) | 2020-08-27 |
| JP2020033370A (ja) | 2020-03-05 |
| US20220409688A1 (en) | 2022-12-29 |
| TW201929848A (zh) | 2019-08-01 |
| EP3733173A4 (en) | 2021-10-27 |
| US11413321B2 (en) | 2022-08-16 |
| CN119326743A (zh) | 2025-01-21 |
| CN111050763B (zh) | 2024-10-11 |
| EP3733173A1 (en) | 2020-11-04 |
| TWI787423B (zh) | 2022-12-21 |
| WO2019131712A1 (ja) | 2019-07-04 |
| MX2020001764A (es) | 2020-07-29 |
| KR20250058075A (ko) | 2025-04-29 |
| JP2020128400A (ja) | 2020-08-27 |
| JP6731129B1 (ja) | 2020-07-29 |
| CN111050763A (zh) | 2020-04-21 |
| AU2024219679A1 (en) | 2024-10-17 |
| TW202308606A (zh) | 2023-03-01 |
| JP6628946B2 (ja) | 2020-01-15 |
| MX2022013816A (es) | 2022-11-30 |
| JPWO2019131712A1 (ja) | 2019-12-26 |
| SG11202000906YA (en) | 2020-03-30 |
| US12343369B2 (en) | 2025-07-01 |
| AU2018396512A1 (en) | 2020-02-13 |
| CA3070854A1 (en) | 2019-07-04 |
| KR20200102978A (ko) | 2020-09-01 |
| JP6765024B2 (ja) | 2020-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20100266532A1 (en) | Methods for inhibiting scarring | |
| Fitzwilliams | The tongue and its diseases | |
| US20250152649A1 (en) | Pharmaceutical composition for use in increasing hair, modifying scalp or skin, healing a wound, promoting osteogenesis, or modifying hair | |
| Yuan et al. | ONO-2506 can delay levodopa-induced dyskinesia in the early stage | |
| HK40030380A (en) | Pharmaceutical composition to be used for increasing hair, modifying scalp or skin, healing wounds, promoting osteogenesis, or modifying hair | |
| AU2024219679B2 (en) | Pharmaceutical composition for use in increasing hair, modifying scalp or skin, healing a wound, promoting osteogenesis, or modifying hair | |
| RU2828557C1 (ru) | Способ хирургического лечения доброкачественных новообразований глоточного отростка околоушных слюнных желез | |
| CN111214645A (zh) | Ghrh-a在制备防治缺血性脑梗塞药物中的应用 | |
| Zhang et al. | Perfusion pressure as a determinant of respiratory function outcomes in unilateral biportal lumbar endoscopic procedures | |
| Xia et al. | A Feasibility Research on Restoration of Demyelination in Trigeminal Nerve with Transnasal Administration of BDNF/NGF Loading on PEG-PLA Nanoparticles | |
| CN119656288A (zh) | 一种多肽在制备预防或治疗脑卒中药物中的应用 | |
| ALOPECIA | INTERNATIONAL RESEARCH JOURNAL OF PHARMACY | |
| JP2025521604A (ja) | 脊髄再生療法 | |
| CN113041339A (zh) | 一种功能性配方食品及其在制备脑出血后继发性脑损伤防治药物中的应用 | |
| CN120837851A (zh) | 一种基于低强度脉冲超声调控构建动物创伤性脑损伤模型的方法及其应用 | |
| CN120531518A (zh) | 一种兔脑干出血模型及其建立方法 | |
| Samson et al. | Comparison of serum lactate dehydrogenase levels in individuals with dysplasia, oral squamous cell carcinoma and normal healthy individuals | |
| Torres et al. | Microsurgery role of salvage surgery for squamous cell carcinoma of the oral cavity: experience in the last 10 years | |
| Martin et al. | Studies from the Biological Laboratory: V. 1-5; 1877/78-1891/93 | |
| Johns Hopkins University. Biological Laboratory | Studies from the Biological Laboratory | |
| Palis | TUMORS AND JAW CYSTS FORMED FROM THE RESIDUAL GLANDULAR EPITHELIUM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |